“Committed to making the difference”
AiCuris is a pharmaceutical company focused on the discovery, research and development of novel, resistance-breaking antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.
Founded in 2006 as a spin-out from Bayer's virology and bacteriology research department, AiCuris is now an established “powerhouse for anti-infectives” and is one of the few biotech companies world-wide to have successfully brought a drug to market, and therefore to patients (Prevymis® 2017/18).
Today AiCuris has an innovative pipeline of anti-infective agents and a team of internationally recognized scientists in Research and Development. By focusing on therapeutic areas with high medical need, the company is positioned for growth and success.
AiCuris changes its legal form
|AiCuris Anti-infective Cures GmbH becomes AiCuris AG|
The Company’s shareholder resolved to change the legal form from the German “GmbH” (limited-liability company) to a stock corporation (Aktiengesellschaft or “AG”). :
BEAT-COV: Entwicklung COVID-19-Medikamente
|Initiative BEAT-COV fordert Unterstützung für Entwicklung und Produktion neuer, innovativer COVID-19-Medikamente|
Winners of the AiCubator Resident Status
|AiCuris selects three novel anti-infective treatment approaches as winners of the AiCubator Resident Status, a corporate innovative accelerator initiative|